Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Related Citations for PubMed (Select 23865428)

1.

Matrix metalloproteinase inhibition in atherosclerosis and stroke.

Roycik MD, Myers JS, Newcomer RG, Sang QX.

Curr Mol Med. 2013 Sep;13(8):1299-313. Review.

PMID:
23865428
2.

Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.

Siasos G, Tousoulis D, Kioufis S, Oikonomou E, Siasou Z, Limperi M, Papavassiliou AG, Stefanadis C.

Curr Top Med Chem. 2012;12(10):1132-48. Review.

PMID:
22519444
3.
4.

Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).

Li NG, Tang YP, Duan JA, Shi ZH.

Expert Opin Ther Pat. 2014 Sep;24(9):1039-52. doi: 10.1517/13543776.2014.937424. Epub 2014 Aug 6. Review.

PMID:
25098768
5.

Is there new hope for therapeutic matrix metalloproteinase inhibition?

Vandenbroucke RE, Libert C.

Nat Rev Drug Discov. 2014 Dec;13(12):904-27. doi: 10.1038/nrd4390. Epub 2014 Nov 7. Review.

PMID:
25376097
6.

Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke.

Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC.

BMC Neurosci. 2006 Jul 17;7:56.

7.

Matrix metalloproteinases in vascular physiology and disease.

Siefert SA, Sarkar R.

Vascular. 2012 Aug;20(4):210-6. doi: 10.1258/vasc.2011.201202. Epub 2012 Aug 15. Review.

PMID:
22896663
8.

Matrix metalloproteinases as valid clinical targets.

Fingleton B.

Curr Pharm Des. 2007;13(3):333-46. Review.

PMID:
17313364
9.

Vascular extracellular matrix in atherosclerosis.

Chistiakov DA, Sobenin IA, Orekhov AN.

Cardiol Rev. 2013 Nov-Dec;21(6):270-88. doi: 10.1097/CRD.0b013e31828c5ced. Review.

PMID:
23422022
10.

Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.

George SJ.

Expert Opin Investig Drugs. 2000 May;9(5):993-1007. Review.

PMID:
11060722
11.

Mmp-9 inhibitors in the brain: can old bullets shoot new targets?

Kaczmarek L.

Curr Pharm Des. 2013;19(6):1085-9. Review.

PMID:
23016686
12.
13.

Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Benjamin MM, Khalil RA.

EXS. 2012;103:209-79. doi: 10.1007/978-3-0348-0364-9_7. Review.

14.

Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.

Chaudhary AK, Pandya S, Ghosh K, Nadkarni A.

Mutat Res. 2013 Jul-Sep;753(1):7-23. doi: 10.1016/j.mrrev.2013.01.002. Epub 2013 Jan 28. Review.

PMID:
23370482
15.

Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.

Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L.

Mediators Inflamm. 2013;2013:928315. doi: 10.1155/2013/928315. Epub 2013 Jun 12. Review.

16.

Hydrogen sulfide and sodium nitroprusside compete to activate/deactivate MMPs in bone tissue homogenates.

Vacek TP, Qipshidze N, Tyagi SC.

Vasc Health Risk Manag. 2013;9:117-23. doi: 10.2147/VHRM.S39508. Epub 2013 Mar 19.

17.

Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins.

Zhang Y, Gu Y, Lee HM, Hambardjieva E, Vrankov√° K, Golub LM, Johnson F.

Curr Med Chem. 2012;19(25):4348-58.

PMID:
22830350
18.

Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.

Briasoulis A, Tousoulis D, Papageorgiou N, Kampoli AM, Androulakis E, Antoniades C, Tsiamis E, Latsios G, Stefanadis C.

Curr Top Med Chem. 2012;12(10):1214-21. Review.

PMID:
22519451
19.

Matrix metalloproteinases (MMPs) in health and disease: an overview.

Malemud CJ.

Front Biosci. 2006 May 1;11:1696-701. Review.

PMID:
16368548
20.

Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities.

Ndinguri MW, Bhowmick M, Tokmina-Roszyk D, Robichaud TK, Fields GB.

Molecules. 2012 Nov 30;17(12):14230-48. doi: 10.3390/molecules171214230.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk